Ultrasound (US) accelerates healing by stimulating the production of bone callus and the process of mineralization. A US system (EXOGEN; Bioventus, Durham, NC, USA) using low intensity pulsed ultrasound (LIPUS) and this principle is FDA-approved. This study analyzed the effectiveness of a novel bimodal acoustic signal (BMAS) for bone fracture healing compared to the clinically used LIPUS system in an animal model. Seventeen mature white New Zealand female rabbits, underwent a bilateral fibula osteotomy as part of an IACUC-approved protocol. Afterwards, each rabbits' legs were randomized to receive 20 minutes treatment daily for 18 days with BMAS or EXOGEN. The latter utilizes a longitudinal ultrasonic mode only, while the former employs US-induced shear stress to promote bone formation. Power Doppler imaging (PDI) was acquired days 0, 2, 4, 7, 11, 14 and 18 post-surgery to monitor treatment response and local inflammation. Images were analyzed off-line using ImageJ (NIH, Bethesda, MD, USA) for amount and intensity of flow. X-rays were acquired to evaluate fractures on days 0, 14, 18 and 21 post-surgery. Rabbits were euthanized day 21 post-surgery, the legs were extracted and their fibulas were analyzed with an electromechanical device to determine maximum torque, initial torsional stiffness and angular displacement at failure. The legs also underwent square CT DEXA analysis to determine the ratio of bone mineral density (BMD) or bone mineral content (BMC) values at the fracture level over normal bone values. ANOVAs and paired t-tests were used to compare pairwise outcome variables for the 2 treatment modes on a per rabbit basis. The BMAS system induced better fracture healing with greater stiffness (0.042 +/- 0.099 Ncm/deg, p = 0.050) and torque (1.574 +/- 2.953 Ncm, p = 0.022) at the fracture sites than the LIPUS (EXOGEN) system. Quantitative PDI assessments showed a higher relative amount of vascularity (i.e., difference in pixel counts) with LIPUS (EXOGEN) than BMAS on days 4 and 18 (p < 0.04). The BMD and BMC analysis showed no significant statistical difference between BMAS and LIPUS (EXOGEN); p > 0.25. The novel BMAS technique achieved better bone fracture healing response than the current FDA-approved LIPUS (EXOGEN) system.